Bridgewater Associates LP Has $335,000 Holdings in Amedisys, Inc. (NASDAQ:AMED)

Bridgewater Associates LP cut its stake in Amedisys, Inc. (NASDAQ:AMED) by 71.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 3,686 shares of the health services provider’s stock after selling 9,138 shares during the period. Bridgewater Associates LP’s holdings in Amedisys were worth $335,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently modified their holdings of AMED. Blue Trust Inc. raised its position in Amedisys by 55.1% in the 4th quarter. Blue Trust Inc. now owns 349 shares of the health services provider’s stock worth $34,000 after purchasing an additional 124 shares during the last quarter. HBW Advisory Services LLC acquired a new position in shares of Amedisys during the fourth quarter valued at $38,000. Versant Capital Management Inc lifted its stake in shares of Amedisys by 68.5% during the fourth quarter. Versant Capital Management Inc now owns 450 shares of the health services provider’s stock valued at $41,000 after acquiring an additional 183 shares during the period. Vestcor Inc acquired a new stake in Amedisys in the fourth quarter worth about $73,000. Finally, Venturi Wealth Management LLC raised its holdings in Amedisys by 397.4% during the 4th quarter. Venturi Wealth Management LLC now owns 975 shares of the health services provider’s stock worth $89,000 after purchasing an additional 779 shares during the last quarter. 94.36% of the stock is currently owned by institutional investors and hedge funds.

Amedisys Trading Down 0.2 %

Shares of NASDAQ AMED opened at $91.76 on Friday. Amedisys, Inc. has a twelve month low of $82.15 and a twelve month high of $98.95. The stock has a market cap of $3.01 billion, a price-to-earnings ratio of 36.41, a P/E/G ratio of 1.78 and a beta of 0.89. The company has a quick ratio of 1.19, a current ratio of 1.19 and a debt-to-equity ratio of 0.05. The company’s fifty day moving average is $92.14 and its 200-day moving average is $91.89.

Amedisys (NASDAQ:AMED) last posted its earnings results on Wednesday, February 26th. The health services provider reported $0.96 earnings per share for the quarter, missing the consensus estimate of $1.05 by ($0.09). The business had revenue of $598.05 million for the quarter, compared to the consensus estimate of $602.38 million. Amedisys had a return on equity of 12.20% and a net margin of 3.57%. Equities research analysts predict that Amedisys, Inc. will post 4.4 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on AMED shares. Royal Bank of Canada reiterated an “outperform” rating and set a $100.00 price target on shares of Amedisys in a research report on Wednesday. Stephens reissued an “equal weight” rating and issued a $101.00 price target on shares of Amedisys in a research note on Tuesday, March 4th. Four investment analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $100.75.

Amedisys Company Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.